Gaurav Agarwal is a Nephrology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
619 19th St S
Birmingham, AL 35249
Telephone
205-934-4011Provider last certified this registry record 29 Mar 2023.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Chiesi USA, Inc.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
- Alexion Pharmaceuticals, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
40.5%Beta blocker10.8%Carvedilol74%Metoprolol Tartrate13%Metoprolol Succinate12%Part D≥123 patientsCalcium channel blocker8.4%Amlodipine Besylate64%Nifedipine Er36%Part D≥84 patients+ 9 more classes in this area
Metabolism & gastrointestinal
25%Corticosteroid12.4%Prednisone100%Part D≥180 patientsProton pump inhibitor8.9%Pantoprazole Sodium88%Omeprazole8%Esomeprazole Magnesium4%Part D<11 patients+ 4 more classes in this area
Anti-infectives
21.2%Short-acting sulfonamides17.6%Sulfamethoxazole-Trimethoprim100%Part D≥248 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor1.9%Valganciclovir Hcl100%Part D≥42 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- 4/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center
University of Alabama at Birmingham
FY2026$89,350U01DK115997 - 4/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center
University of Alabama at Birmingham
FY2025$306,100U01DK115997 - 4/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center
University of Alabama at Birmingham
FY2024$310,000U01DK115997
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Andrew Levey, MD
Tufts Medical Center
Bertram Kasiske, MD
Hennepin Healthcare
Garabed Eknoyan, MD
Baylor College of Medicine
Lawrence Hunsicker, MD
University of Iowa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”